Johansen OE. Interpretation of cardiovascular outcome trials in type 2 diabetes needs a multiaxial approach. World J Diabetes 2015; 6(9): 1092-1096 [PMID: 26265995 DOI: 10.4239/wjd.v6.i9.1092]
Corresponding Author of This Article
Odd Erik Johansen, MD, PhD, Medical Director, Boehringer Ingelheim Norway KS, P.O. Box 405, 1373 Asker, Norway. odd_erik.johansen@boehringer-ingelheim.com
Research Domain of This Article
Endocrinology & Metabolism
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Diabetes. Aug 10, 2015; 6(9): 1092-1096 Published online Aug 10, 2015. doi: 10.4239/wjd.v6.i9.1092
Interpretation of cardiovascular outcome trials in type 2 diabetes needs a multiaxial approach
Odd Erik Johansen
Odd Erik Johansen, Boehringer Ingelheim Norway KS, 1373 Asker, Norway
Odd Erik Johansen, Department of Medical Research, Bærum Hospital, Vestre Viken Hospital Trust, 1309 Rud, Norway
Author contributions: Johansen OE prepared and wrote this editorial.
Conflict-of-interest statement: I am employed by Boehringer Ingelheim Norway KS.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Odd Erik Johansen, MD, PhD, Medical Director, Boehringer Ingelheim Norway KS, P.O. Box 405, 1373 Asker, Norway. odd_erik.johansen@boehringer-ingelheim.com
Telephone: +47-91817674 Fax: +47-66761330
Received: January 20, 2015 Peer-review started: January 22, 2015 First decision: March 6, 2015 Revised: June 25, 2015 Accepted: July 21, 2015 Article in press: July 23, 2015 Published online: August 10, 2015
Core Tip
Core tip: Vasculopathy and cardiovascular (CV) manifestations in patients with type 2 diabetes differ dependent on disease duration. This literature review supports that it is necessary to contextualize results of CV outcome trials in diabetes to diabetes duration as well as duration and mode of action of the intervention, which may be of particular relevance for those interventions that primarily target pathways related to atherosclerotic processes, organ-remodelling, or vessel integrity. Several CV outcome trials testing newer therapy classes (i.e., di-peptidyl peptidase-4 inhibitors, glucagon-like protein-1 receptor analogues and sodium glucose co-transporter-2 inhibitors) are now due to report and a multiaxial approach to interpret these results is needed.
